Polyclonal antibody stimulator (Cancer Advances)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePolyclonal antibody stimulator (Cancer Advances)
Drug Alias NamePAS多克隆抗体刺激器 - Cancer AdvancesGastrimmuneAnti-gastrin 17 immunogenInsegia +[6] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsGastrin 17 inhibitors
TargetsGastrin 17
Therapy Area/IndicationsJaundiceDiabetes Mellitus, Type 1Pancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAphton Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, Los Angeles
Inactive CompaniesCancer Advances Inc
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsJaundicePancreatic NeoplasmsStomach Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A